Cardio Diagnostics (CDIO) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardio Diagnostics is the larger company by market cap ($5.7 million vs $2.6 million), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CDIO | VRAX |
|---|---|---|
| Share price | $1.93 | $1.95 |
| Market cap | $5.70M | $2.62M |
| 1-day change | -2.28% | -7.58% |
| EPS (TTM) | $-2.91 | $-12.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.91 | $21.75 |
| 52-week low | $0.97 | $1.83 |
| Distance from 52-week high | -75.66% | -91.03% |
| Average volume | 55.63K | 1.77M |
| Shares outstanding | 2.96M | 1.34M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cardio Diagnostics is about 2.2 times larger than Virax Biolabs Group by market value ($5.70M vs $2.62M).
CDIO vs VRAX FAQ
Which is bigger, Cardio Diagnostics or Virax Biolabs Group?
Cardio Diagnostics (CDIO) is larger, with a market capitalization of $5.70M compared with $2.62M for Virax Biolabs Group (VRAX).
Are Cardio Diagnostics and Virax Biolabs Group in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.